EMCDDA Home
  • EN
Search

Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users

EMCDDA, Lisbon, November 2010

Publication type:

Manuals

Summary:

Infectious diseases are among the most serious health consequences of injecting drug use and can lead to significant healthcare costs. Injecting drug users are vulnerable to a range of infectious and communicable diseases through a variety of risk behaviours, and because of underlying conditions such as poor hygiene, homelessness and poverty.

There is a recognised need for guidance on providing IDUs with a medical examination and testing for HIV, viral hepatitis and several other infections on a regular basis. In addition, improving testing uptake in this group would benefit epidemiological surveillance and monitoring as carried out at the national and international level.

These guidelines are accompanied by a recommended package of prevention and primary care in relation to injecting drug users and infections. Treatment and other specialist care are not discussed in detail but are dealt with by indicating referral to appropriate services.

Download as pdf (664Kb):

English (en)

Table of contents

  • Acknowledgements
  • Preface
  • Summary
  • Methodology and scope
  • Part 1: Guidelines for voluntary medical examination, testing and counselling
  • Chapter 1: Introduction
  • Chapter 2: Providing medical examination, testing and counselling to IDUs
  • Part 2: Background and implementation of the guidelines
  • Chapter 3: Background
  • Chapter 4: Implementation
  • References
  • Abbreviations
  • Glossary

Pages:

80

Price:

free

ISBN/ISSN:

978-92-9168-414-4

Catalogue number:

TD3009243ENC

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00

More contact options >>

Page last updated: Wednesday, 20 August 2014